Knowledge Is Power: How Early Detection Can Transform Alzheimer’s Care
New tools and evidence can empower early action against Alzheimer’s before symptoms strike
Why Elderly Americans Are Bearing the Brunt of the Government Shutdown’s Impact
Time is of the essence, particularly for those with cognitive conditions. The loss of telehealth flexibilities, combined with disruptions to Medicaid, could have devastating consequences for millions of patients with dementia and other cognitive and behavioral conditions.
presented by
MedCity News Pivot Podcast: How Emergency Departments Are Using Real-Time Data to Improve Outcomes
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
Alzheimer’s Therapy Is Coming to the Home With FDA Approval of Injectable Eisai, Biogen Drug
Injectable Leqembi permits weekly maintenance dosing of the Eisai and Biogen Alzheimer’s disease drug that may be done at a patient’s home. Other recent notable regulatory news includes several rare disease drug approvals and narrower FDA nods for Covid-19 vaccines.
Isaac Health Raises $10.5M for its Specialist-Led Dementia Care Model
Isaac Health, a startup specializing in cognitive care for Alzheimer’s dementia , raised $10.5 million in Series A funding to expand nationwide access to its platform. The company partners with health plans to provide screening, specialist diagnosis, treatment, and ongoing management aimed at slowing cognitive decline.
Sanofi’s Neuro Pipeline Expands to Alzheimer’s With $470M Vigil Neuroscience Acquisition
The Alzheimer’s disease drugs that have reached the market in the past two years are antibodies designed to break up amyloid plaques. Vigil Neuroscience brings to Sanofi a different approach: an oral small molecule designed to activate microglia, immune cells that play a key role in brain health.
Alzheimer’s Disease Now Has Its First FDA-Cleared Blood Test
Fujirebio Diagnostics’ blood test for Alzheimer’s disease offers a less expensive and less invasive alternative compared to medical imaging and tests of cerebrospinal fluid. But competition looms from blood-based tests in development by other diagnostics companies.
presented by
Enhanced Direct Enrollment: Georgia Access and the Power of Partnership
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
The Biggest Opportunity for AI in Healthcare Isn’t Disease, It’s Wellness
By shifting the focus for consumers earlier in the care continuum, AI has the potential to play a transformative role in prevention and personalized health solutions-particularly for health conditions that impact hundreds of millions of people worldwide.
Alzheon’s Precision Medicine Approach to Resurrect an Alzheimer’s Drug Fails Pivotal Study
Alzheon hoped testing its drug in a genetically defined subgroup of Alzheimer’s disease patients would succeed, overcoming earlier clinical trial failures. Instead, preliminary results show the pill failed to outdistance a placebo.
GSK Grabs Rights to Technology That Gets Drugs Across the Blood-Brain Barrier
GSK is licensing an ABL Bio technology that yields bispecific antibodies engineered to leverage a certain transmembrane receptor to cross the blood-brain barrier to treat neurodegeneration. GSK is already partnered with Alector, which has monoclonal antibodies in clinical development for Alzheimer’s disease.
Why Blood is Best: Transforming the Diagnostic Journey for Alzheimer’s Disease
As the pool of approved therapies continues to (hopefully) expand, the clinical and diagnostic testing communities need to do a better job at ensuring the right patients move through this journey more quickly – and accurately – to improve their health and prognosis.
presented by
RCM Outsourcing: Balancing Human Expertise & Smart Technology
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
Transforming Our Collective Approach to Alzheimer’s Disease Care Begins with Early and Accurate Diagnosis
While advancements in diagnostics are promising, the need remains for healthcare professionals to take the lead on proactive conversations with patients and their loved ones about the early signs and symptoms of Alzheimer’s disease.
Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data
One Phase 3 test of Auvelity met its main goal in Alzheimer’s agitation while the drug’s other pivotal trial showed numerical improvement that fell short of statistical significance. Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimer’s agitation drug.
Why We Urgently Need More Widely Available Tests for Alzheimer’s Disease
Early diagnosis through blood tests buys invaluable time – for patients and their families to plan, seek support, make informed decisions about their difficult care journey and, perhaps most importantly, be together.
Through Early Discussions About Elder Care, Doctors Can Empower Seniors to Age in Place
The vast majority of older adults want to age at home. To support that goal, doctors should encourage them to consider their care options — long before they need assistance.
AbbVie Adds Another Alzheimer’s Prospect With $1.4B Aliada Therapeutics Acquisition
Aliada brings AbbVie an early clinical Alzheimer’s disease drug candidate as well as the platform technology that produced it. Aliada licensed its brain delivery technology from Johnson & Johnson.